The Risk Of Renal Impairment In Hormone-Refractory Prostate Cancer Patients With Bone Metastases Treated With Zoledronic Acid
July 7th, 2008 Posted in hormone therapyNearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment according to a report by Dr. Oh and colleagues in the online version of Cancer.
ZA is an intravenous bisphosphonate given to decrease skeletal related events in CaP patients with bone metastases. In a phase III trial, ZA was associated with renal impairment in 17% of cases. The present study is the first observational study that quantifies the rate or renal impairment and identifies associated risk factors. Renal impairment in this analysis was defined as any one of the following; an increase in the serum creatinine of >0.5mg/dL over the initial level for initial values <1.4mg/dL, or an increase of >1.0mg/dL over the initial level for initial values >1.4mg/dL. Secondary definitions of renal impairment included severity degrees of calculated creatinine levels.